Predicting whether Compass Therapeutics (CMPX) stock will appreciate depends heavily on upcoming clinical trial data readouts, regulatory milestone approvals for its lead oncology asset, and overall market sentiment toward speculative biotechnology equities. While positive clinical developments can trigger sharp upward momentum, pre-revenue biotech valuations carry inherent volatility and clinical trial risk.